

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re: Apple Tree Life Sciences, Inc., <i>et al.</i> , ¹ Debtors.	Chapter 11 Case No. 25-12177 (LSS) (Jointly Administered)
--	---

AMENDED JOINT EXHIBIT LIST FOR THE HEARING ON FEBRUARY 25, 2026

Parties in interest Rigmora Biotech Investor One LP, by its general partner Unicorn Biotech Ventures One Ltd, and Rigmora Biotech Investor Two LP, by its general partner Unicorn Biotech Ventures Two Ltd (collectively, the “LPs”), and the above-captioned debtors and debtors in possession (the “**Debtors**,” and with the LPs, the “**Parties**”) by and through their undersigned counsel, hereby provide this joint exhibit list (the “**Exhibit List**”) identifying the exhibits the Parties introduced into evidence in connection with the *Motion of Rigmora Biotech Investor One LP and Rigmora Biotech Investor Two LP for Relief from the Automatic Stay* [Dkt. 125]; and the *Amended Motion of Rigmora Biotech Investor One LP and Rigmora Biotech Investor Two LP for an Order Dismissing the Bankruptcy Cases of ATP Life Science Ventures L.P. and ATP III GP, Ltd.* [Dkt. 204] heard at the hearing scheduled on February 25, 2026 at 10:00 a.m. (ET) (the “**Hearing**”) before the Honorable Laurie S. Silverstein, at the United States Bankruptcy Court for the District of Delaware, 824 N. Market Street, 6th Floor, Courtroom No. 2, Wilmington, Delaware 19801. Attached as **Exhibit A** is a redline against the parties’ joint exhibit list filed on February 25, 2026.

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors’ service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.



EXHIBITS

The Parties identify the following exhibits admitted in connection with the matters to be heard. The Parties reserve the right to ask the Court to take judicial notice of pleadings, transcripts, and/or documents filed in or in connection with the above-captioned cases. The parties have met and conferred concerning the exhibits highlighted in yellow but have not been able to reach agreement as to the introduction of those exhibits into the record.

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	ENTERED IN EVIDENCE
JX-0	DX-5	RX-0	First Amended and Restated Limited Partnership Agreement ("LPA")	ATP_00202247		2/25 Tr. 81:20-82:1
JX-1	--	RX-1	LPA Amendment No. 1	ATP_00202344		2/25 Tr. 81:20-82:1
JX-2	DX-18	RX-2	LPA Amendment No. 2	ATP_00202349		2/25 Tr. 81:20-82:1
JX-3	DX-19	RX-3	LPA Amendment No. 3	ATP_00202357		2/25 Tr. 81:20-82:1
JX-4	DX-20	RX-4	LPA Amendment No. 4	ATP_00202362		2/25 Tr. 81:20-82:1
JX-5	DX-21	RX-5	LPA Amendment No. 5	ATP_00202365		2/25 Tr. 81:20-82:1
JX-6	DX-22	RX-6	LPA Amendment No. 6	ATP_00202375		2/25 Tr. 81:20-82:1
JX-7	DX-23	RX-7	LPA Amendment No. 7	ATP_00202378		2/25 Tr. 81:20-82:1
JX-8	DX-24	RX-8	LPA Amendment No. 8	ATP_00202383		2/25 Tr. 81:20-82:1

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	ENTERED IN EVIDENCE
JX-9	DX-25	RX-9	LPA Amendment No. 9	ATP_00202388		2/25 Tr. 81:20-82:1
JX-10	DX-26	RX-10	LPA Amendment No. 10	ATP_00202407		2/25 Tr. 81:20-82:1
JX-11	DX-27	RX-11	LPA Amendment No. 11	ATP_00202412		2/25 Tr. 81:20-82:1
JX-12	DX-28	RX-12	LPA Amendment No. 12	ATP_00202416		2/25 Tr. 81:20-82:1
JX-13	DX-29	RX-13	LPA Amendment No. 13	ATP_00202424		2/25 Tr. 81:20-82:1
JX-14	DX-30	RX-14	LPA Amendment No. 14	ATP_00202429		2/25 Tr. 81:20-82:1
JX-15	DX-31	RX-15	LPA Amendment No. 15	ATP_00202437		2/25 Tr. 81:20-82:1
JX-16	DX-32	RX-16	LPA Amendment No. 16	ATP_00202440		2/25 Tr. 81:20-82:1
JX-17	DX-33	RX-17	LPA Amendment No. 17	ATP_00202444		2/25 Tr. 81:20-82:1
JX-18	DX-34	RX-18	LPA Amendment No. 18	ATP_00202461		2/25 Tr. 81:20-82:1
JX-19	DX-35	RX-19	LPA Amendment No. 19	ATP_00202477		2/25 Tr. 81:20-82:1
JX-20	DX-36	RX-20	LPA Amendment No. 20	ATP_00260368		2/25 Tr. 81:20-82:1
JX-21	DX-37	RX-21	LPA Amendment No. 21	ATP_00202482		2/25 Tr. 81:20-82:1
JX-22	DX-38	RX-22	LPA Amendment No. 22	ATP_00202487		2/25 Tr. 81:20-82:1

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	ENTERED IN EVIDENCE
JX-23	DX-15	RX-23	Nine Square Therapeutics, Inc. Series A Preferred Stock Purchase Agreement	ATP_00001600		2/25 Tr. 237:4-238:19
JX-24	DX-12	RX-24	Initial (Opal Biosciences, Inc) Series A Preferred Stock Purchase Agreement	ATP_00001104		2/25 Tr. 237:4-238:19
JX-25	DX-14	RX-25	Nereid Therapeutics Inc. Preferred Stock Purchase Agreement	ATP_00001242		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-26	DX-10	RX-26	Aulos Biosciences, Inc. Series A Preferred Stock Purchase Agreement	ATP_00000678		2/25 Tr. 237:4-238:19
JX-27	DX-13	RX-27	Apertor Pharmaceuticals, Inc Series A Preferred Stock Purchase Agreement	ATP_00000627		2/25 Tr. 237:4-238:19
JX-28	DX-1	RX-28	Marlinspike Therapeutics Inc. Series A Preferred Stock Purchase Agreement	ATP_00334406		2/25 Tr. 237:4-238:19
JX-29	DX-11	RX-29	Evercrisp Biosciences, Inc. Series A Preferred Stock Purchase Agreement	ATP_00334675		2/25 Tr. 237:4-238:19
JX-30	DX-16	RX-30	Red Queen Therapeutics Inc Series A Preferred Stock Purchase Agreement	ATP_00001669		2/25 Tr. 237:4-238:19
JX-31	DX-8	RX-31	Aethon Therapeutics, Inc. Series A Preferred Stock Purchase Agreement	ATP_00000546		2/25 Tr. 237:4-238:19
JX-32	--	RX-32	Deep Apple Therapeutics, Inc. Series A Preferred Stock Purchase Agreement	ATP_00088318		2/25 Tr. 237:4-238:19

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	ENTERED IN EVIDENCE
JX-33	--	RX-33	Ascidian Therapeutics, Inc. Series A Preferred Stock Purchase Agreement	ATP_00322023		2/25 Tr. 237:4-238:19
JX-34	--	RX-34	Marengo Therapeutics, Inc. Series B Preferred Stock Purchase Agreement	ATP_00284891		2/25 Tr. 237:4-238:19
JX-35	--	RX-35	Replicate Bioscience, Inc. Series A Preferred Stock Purchase Agreement	ATPBK_00016512		2/25 Tr. 237:4-238:19
JX-37	--	RX-37	ATP Life Sciences Ventures L.P., Chapter 11 Petition	Dkt. 1 (Case No. 25-12178)		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-38	--	RX-38	ATP III GP, Ltd., Chapter 11 Petition	Dkt. 1 (Case No. 25-12179)		2/26 Tr. 161:20-24
JX-49	--	RX-49	ATP III GP, Ltd., Schedule of Assets and Liabilities	Dkt. 241		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-50	--	RX-50	ATP III GP, Ltd., Statement of Financial Affairs	Dkt. 242		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-51	--	RX-51	ATP Life Science Ventures, L.P., Schedule of Assets and Liabilities	Dkt. 238		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-52	--	RX-52	ATP Life Science Ventures, L.P., Statement of Financial Affairs	Dkt. 240		The Parties stipulate that this joint exhibit be admitted into evidence.

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	ENTERED IN EVIDENCE
JX-58	--	RX-56	Funding and DIP Motion Hearing Transcript, February 19, 2026			2/25 Tr. 238:1-17
JX-62	--	RX-58	Cayman Winding Up Petition	Dkt. 125, Ex. P	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein	The Parties stipulate that this joint exhibit be admitted into evidence.
JX-63	DX-1	RX-59	Cayman Amended Winding-Up Petition, Nov. 21, 2025	Dkt. 125, Ex. B	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein	The Parties stipulate that this joint exhibit be admitted into evidence.
JX-64	--	RX-60	Cayman Amended Defence to Winding-Up Petition, Nov. 17, 2025	Dkt. 125, Ex. BB	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein	The Parties stipulate that this joint exhibit be admitted into evidence.
JX-65	DX-48	--	<i>Rigmora's Amended Reply to the Amended Defense to the Amended Winding Up Petition</i> , dated November 24, 2025		The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein	The Parties stipulate that this joint exhibit be admitted into evidence.
JX-66	--	RX-61	Cayman PTR Tr., Dec. 17, 2025	Dkt. 125, Ex. AA		The Parties stipulate that this joint exhibit be admitted into evidence.

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	ENTERED IN EVIDENCE
JX-68	DX-49	RX-63	Petitioners' Cayman Skeleton Argument, Dec. 16, 2025	Dkt. 125, Ex. R	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein	The Parties stipulate that this joint exhibit be admitted into evidence.
JX-69	--	RX-170	2025.12.17 Procedural Trial Scheduling Order			The Parties stipulate that this joint exhibit be admitted into evidence.
JX-87	DX-46	RX-92	Email from D. Kaprow to Quinn Emanuel attaching proposed form of order, Dec. 8, 2025	RIGMORA_BK00000143		2/25 Tr. 41-42
JX-99	--	RX-105	Declaration of Ilya Strebulaev	Dkt. 365	Debtors: Hearsay	The parties stipulate that sections III and V of this joint exhibit be admitted into evidence.
JX-106	--	RX-112	Email from S. Harrison to Y. Bogdanov, May 11, 2025	RIGMORA00062977		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-112	DX-3	RX-118	Grant Thornton 2024 Audited Financials	ATP_00089374		2/26 Tr. 146:3-11
JX-115	--	RX-121	2024 ATP LSV Financial Statements	ATP_00000253		2/26 Tr. 179-180
JX-116	DX-64	RX-122	December 2025 Portfolio Lift Out Deck		This exhibit will be submitted under seal at Debtors' request due to confidentiality considerations, with a	The Parties stipulate that this joint exhibit be admitted into evidence, subject to the LPs' objection that statements therein

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	ENTERED IN EVIDENCE
					sealing motion to follow.	should not be taken for the truth of the matter asserted.
JX-120	--	RX-125	Debtors' DIP Funding Motion & DIP Term Sheet, 13 Feb. 2026	Dkt. 313	LPs: assertions in DIP Funding Motion not to be taken for truth of the matter asserted	2/26 Tr. 55:2-10
JX-123	--	RX-128	Debtors' Responses and Objections to Second Set of Requests for Production and Interrogatories, February 2, 2026			The Parties stipulate that this joint exhibit be admitted into evidence.
JX-125	--	RX-130	Debtors' Supplemental Responses and Objections to Second Set of Requests for Production and Interrogatories, February 16, 2026			The Parties stipulate that this joint exhibit be admitted into evidence.
JX-131	DX-7	--	<i>Parent Pledge Agreement, dated 2023</i>	Docket No. 245-9	LPs: Relevance	3/3 – Debtors propose stipulating into evidence
JX-132	DX-52	--	<i>Email from Daniel Finkelman to Yuri Bogdanov, et al., with attachments Regarding Second Amendment to Loan Agreement, dated between March 9 and June 11, 2025</i>	ATPBK_00064373 - ATPBK_00064399	LPs: Hearsay; Relevance	3/3 – Debtors propose stipulating into evidence
JX-133	DX-53	--	<i>Email from Patrik Blochlinger to Daniel Finkelman, et al. Regarding Second Amendment to Loan</i>	ATPBK_00064400 - ATPBK_00064417	LPs: Hearsay; Relevance	3/3 – Debtors propose stipulating into evidence

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	ENTERED IN EVIDENCE
			<i>Agreement, dated between March 9 and June 11, 2025</i>			
JX-143	--	RX-174	Q3 2025 ATP Fund Digest	ATPBK_00006631		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-144	--	RX-175	Q4 2025 ATP Fund Digest			2/26 Tr. 117:12-22
JX-147	--	RX-178	Aulos Series A-1 Stock Purchase Agreement (January 24, 2025 Closing)	ATP_00000710		2/25 Tr. 237:4-238:19
JX-148	--	RX-179	Replicate Stock Purchase Agreement (inclusive of all tranches)	ATP_00310825		2/25 Tr. 237:4-238:19
JX-149	--	RX-180	Elstar Series A SPA	GT_0001616		2/25 Tr. 237:4-238:19
JX-150	--	RX-181	Galvanize Series B SPA	ATP_00219040		2/25 Tr. 237:4-238:19
JX-151	--	RX-182	Galvanize Series C SPA	ATP_00409203		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-152	--	RX-183	Limelight Series A2 SPA	ATP_00196274		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-161	--	RX-192	Letter from Walkers to Campbells, September 8, 2025			The Parties stipulate that this joint exhibit be admitted into evidence.
JX-171	--	RX-202	Emails from Bogdanov to Harrison re: capital calls	RIGMORA_BK00002643		2/25 Tr. 34:11-18

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	ENTERED IN EVIDENCE
JX-172	--	RX-203	Q2 2025 ATP Fund Digest			2/26 Tr. 117:6-10
JX-173	DX-68	--	<i>Email Between Anna Batarina and Anna Kolonchina Regarding New Deal Documentation for Apertor, dated October 16, 2020, with Attachments</i>	Chancery JX0114	LPs: Hearsay; Relevance	3/3 – Debtors propose stipulating into evidence
JX-175	DX-70	--	<i>Email Between Anna Batarina and Anna Kolonchina Regarding Evercrisp Investment Memorandum, CFIUS Memo, Budget and Capital Call, dated July 23, 2021, with Attachments</i>	Chancery JX0243	LPs: Hearsay; Relevance	3/3 – Debtors propose stipulating into evidence
JX-176	DX-71	--	<i>Email Between Anna Batarina and Anna Kolonchina Regarding Red Queen Investment Memorandum, CFIUS Memo, Budget and Capital Call, dated September 29, 2021, with Attachments</i>	Chancery JX0269	LPs: Hearsay; Relevance	3/3 – Debtors propose stipulating into evidence
JX-178	DX-73	--	<i>Email Between Anna Batarina and Anna Kolonchina Regarding</i>	Chancery JX0312	LPs: Hearsay; Relevance	3/3 – Debtors propose stipulating into evidence

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	ENTERED IN EVIDENCE
			<i>Marlinspike Investment Memorandum, CFIUS Memo, Budget and Capital Call, dated December 14, 2021, with Attachments</i>			
JX-187	DX-82	--	<i>Ex Parte Injunction Order, Cause No. FSD 2025-0146, dated June 20, 2025</i>	--	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein	The Parties stipulate that this joint exhibit be admitted into evidence.
JX-188	DX-83	--	<i>Summons to Appoint Joint Provisional Liquidators, Cause No. FSD 2025-0151, dated September 17, 2025</i>	--	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein	The Parties stipulate that this joint exhibit be admitted into evidence.
JX-199	DX-94	--	<i>Email from Yuri Bogdanov Regarding Liquidity Crisis, dated November 10, 2022</i>	Chancery JX463		2/25 Tr. 53:3-18
JX-200	DX-95	--	<i>Email from Yuri Bogdanov to Seth Harrison, dated May 15, 2025</i>	Chancery JX1318		2/25 Tr. 56:5-11
JX-201	DX-96	--	<i>Deep Apple Press Release, dated June 11, 2025</i>	Chancery JX1428	LPs: object to the extent offered for truth of statements therein	2/25 Tr. 63:7-24 (admitted for limited purpose of the fact that it publicly announces and discusses transaction)

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	ENTERED IN EVIDENCE
JX-228	DX-123	--	<i>Q1 2025 ATP Fund Digest</i>			The Parties stipulate that this joint exhibit be admitted into evidence.
JX-229	DX-124	--	Email from J. Trenkle (Novo) to S. Harrison dated November 19, 2023	ATP_00361287		2/26 Tr. 105-107 (admitted for limited purposes in light of hearsay objection)
JX-230	--	RX-204	Second Witness Statement of Dr. Seth Harrison (Trial Statement), Cause FSD 146 of 2025 (Cayman Proceedings) dated December 8, 2025			The Parties stipulate that this joint exhibit be admitted into evidence subject to hearsay rules and exceptions.
JX-231	DX-125	--	<i>Emails Regarding Evercrisp Capital Call</i> , dated January 23, 2025	Chancery JX-1153	LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026	3/3 – Debtors propose stipulating into evidence
JX-232	DX-126	--	<i>Emails Regarding Aethon and Marlinspike Budgets</i> , dated July 2, 2024	ATP_00123898	LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026	3/3 – Debtors propose stipulating into evidence
JX-233	DX-127	--	<i>Emails Regarding Portfolio Company Budgets</i> , dated July 3, 2024	ATP_00143664	LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at	3/3 – Debtors propose stipulating into evidence

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	ENTERED IN EVIDENCE
					start of trial and first proposed to be added on 3/3/2026	
JX-234	DX-128	--	<i>Emails Regarding Deep Apple Capital Call</i> , dated July 30, 2024	ATP_00083128	LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026	3/3 – Debtors propose stipulating into evidence
JX-235	DX-129	--	<i>Emails Regarding Evercrisp Capital Calls</i> , dated August 19, 2024	ATP_00082118	LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026	3/3 – Debtors propose stipulating into evidence
JX-236	DX-130	--	<i>Emails Regarding Deep Apple Capital Calls</i> , dated October 17, 2024	ATP_00453257	LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026	3/3 – Debtors propose stipulating into evidence
JX-237	DX-131	--	<i>Emails Regarding Deep Apple Capital Call</i> , dated January 8, 2025	ATP_00080694	LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026	3/3 – Debtors propose stipulating into evidence

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	ENTERED IN EVIDENCE
JX-238	DX-132	--	<i>Emails Regarding Evercrisp Capital Call, dated January 23, 2025</i>	ATP_00080770	LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026	3/3 – Debtors propose stipulating into evidence
JX-239	DX-133	--	<i>Emails Regarding Evercrisp Capital Call, dated January 23, 2025</i>		LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026	3/3 – Debtors propose stipulating into evidence
JX-240	DX-134	--	<i>Email Regarding Portfolio Company Capital Calls, dated February 1, 2025</i>	ATP_00119671	LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026	3/3 – Debtors propose stipulating into evidence
JX-241	DX-135	--	<i>Emails Regarding Portfolio Company Funding, dated April 24, 2025</i>	ATP_00039403	LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026	3/3 – Debtors propose stipulating into evidence
JX-242	DX-136	--	<i>The Partnership's Skeleton Argument for the PTR Hearing on 17 December 2025</i>		The parties agree that pleadings from the Cayman case shall not be taken as truth of the	The Parties stipulate that this joint exhibit be admitted into evidence.

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	ENTERED IN EVIDENCE
					matters asserted therein	

AUTHORITIES

JOINT AUTHORITY	DEBTORS' AUTHORITY (DA)	RIGMORA AUTHORITY (RA)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS
JA-1	DA-1	--	<i>Voluntary Petition</i> , In re Sea Launch Company, LLC, No. 09-12153 (BLS) [Docket No. 1]	Docket No. 244-1	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-2	DA-2	--	<i>Declaration of Brett A. Carman in Support of Chapter 11 Petitions and First Day Motions</i> , In re Sea Launch Company, LLC, No. 09-12153 (BLS) [Docket No. 4]	Docket No. 244-2	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-3	DA-3	--	<i>Findings of Fact, Conclusions of Law, and Order Confirming the Debtors' Second Amended Plan of Reorganization</i> , In re Sea Launch Company, LLC, No. 09-12153 (BLS) [Docket No. 923]	Docket No. 244-3	
JA-4	DA-4	--	<i>Voluntary Petition</i> , In re MatlinPatterson Global Opportunities Partners II L.P., No. 21-11255 (DSJ) [Docket No. 1]	Docket No. 244-4	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-5	DA-5	--	<i>Declaration of Matthew Doheny, Chief Restructuring Officer of the Debtors, in Support of Chapter 11 Petitions and First Day Motions In Compliance with Local Rule 1007-2</i> , In re MatlinPatterson Global Opportunities Partners	Docket No. 244-5	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence

JOINT AUTHORITY	DEBTORS' AUTHORITY (DA)	RIGMORA AUTHORITY (RA)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS
			II L.P., No. 21-11255 (DSJ) [Docket No. 2]		
JA-6	DA-6	--	<i>Findings of Fact, Conclusions of Law, and Order (I) Confirming the Debtors' Second Amended Joint Chapter 11 Plan of Liquidation and (II) Approving the Related Disclosure Statement on a Final Basis, In re MatlinPatterson Global Opportunities Partners II L.P., No. 21-11255 (DSJ) [Docket No. 915]</i>	Docket No. 244-6	
JA-7	DA-7	--	<i>Voluntary Petition, In re Petra Offshore Fund LP, No. 10-15501 (SCC) [Docket No. 1]</i>	Docket No. 244-7	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-8	DA-8	--	<i>Affidavit Pursuant to Local Rule 1007-2, In re Petra Fund REIT Corp., No. 10-15500 (SCC) [Docket No. 2]</i>	Docket No. 244-8	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-9	DA-9	--	<i>Order Confirming Second Amended Plan of Reorganization of Petra Fund REIT Corp. and Petra Offshore Fund, L.P., as Modified, In re Petra Fund REIT Corp., No. 10-15500 (SCC) [Docket No. 259]</i>	Docket No. 244-9	
JA-10	DA-10	--	<i>Chapter 15 Petition for Recognition of a Foreign Proceeding, In re ECM Straits Fund I, LP (in Official</i>	--	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence

JOINT AUTHORITY	DEBTORS' AUTHORITY (DA)	RIGMORA AUTHORITY (RA)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS
			Liquidation), No. 23-12044 (MG) [Docket No. 1]		
JA-11	DA-11	--	<i>Order Granting Recognition and Relief in Aid of a Foreign Main Proceeding Pursuant to Sections 1504, 1509, 1515, 1517, 1520, and 1521 of the Bankruptcy Code, In re ECM Straits Fund I, LP (in Official Liquidation), No. 23-12044 (MG) [Docket No. 15]</i>		
JA-12	DA-12	--	<i>Declaration of Peter Sherwood in Support of Chapter 15 Petition for Recognition as Foreign Main Proceeding, In re ECM Straits Fund I, LP (in Official Liquidation), No. 23-12044 (MG) [Docket No. 4]</i>		LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-13	DA-13	--	<i>Chapter 15 Petition for Recognition of a Foreign Proceeding, In re Platinum Partners Value Arbitrage Fund L.P., No. 16-12925 (SCC) [Docket No. 1]</i>		LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-14	DA-14	--	<i>Order Granting Recognition and Relief in Aid of a ForeignBog Main Proceeding Pursuant to Sections 1504, 1509, 1515, 1517, 1520, and 1521 of the Bankruptcy Code, In re Platinum Partners Value Arbitrage Fund L.P., No. 16-12925 (SCC) [Docket No. 27]</i>		

JOINT AUTHORITY	DEBTORS' AUTHORITY (DA)	RIGMORA AUTHORITY (RA)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS
JA-15	DA-15	--	<i>Declaration of Warren E. Gluck in Support of Recognition as Foreign Main Proceeding to Chapter 15 of the Bankruptcy Code, In re Platinum Partners Value Arbitrage Fund L.P., No. 16-12925 (SCC) [Docket No. 4]</i>		LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-16	DA-16	--	<i>In re Formation Group (Cayman) Fund I L.P (Cayman Grand Ct. Apr. 21, 2022)</i>	Docket No. 245-5	
JA-17	--	RX-66	Exempted Limited Partnership Law (2012 Revision)		
JA-18	DA-17	RX-67	Exempted Limited Partnership Act (2025 Revision)	Dkt. 125, Ex. M	
JA-19	DA-18	RX-68	Companies Act (2025 Revision)	Dkt. 125, Ex. CC	
JA-20	--	RX-69	<i>Re Aquapoint LP, CICA (Civil) Appeal No. 0014 of 2022, 04 October 2023</i>	Dkt. 126, Ex. B-34	
JA-21	DA-19	RX-70	<i>Kuwait Ports Authority v Port Link GP Limited [2023 (1) CILR 50]</i>	Dkt. 125, Ex. O	
JA-22	DA-20	--	<i>Re Aquapoint LP FSD 157 of 2021 (DDJ), KY 2022 GC 69</i>	Docket No. 126 Ex. B-32	
JA-23	DA-21	--	<i>Re Aquapoint LP, CICA (Civil) Appeal No. 0014 of 2022</i>	Docket No. 126 Ex. B-34	
JA-24	--	RX-71	<i>Re Belmont Asset Based Lending Ltd [2010] CIGC J0121-2</i>	Dkt. 125, Ex. C	

JOINT AUTHORITY	DEBTORS' AUTHORITY (DA)	RIGMORA AUTHORITY (RA)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS
JA-25	--	RX-72	<i>Aquapoint LP (in Official Liquidation) v Xiaohu Fan</i> , [2025] UKPC 56	Dkt. 125, Ex. K	
JA-26	--	RX-73	<i>In Re One Thousand & One Voices Africa Fund I LP</i> , KY 2024 GC 62, 9 May 2024	Dkt. 125, Ex. D	
JA-27	--	RX-74	<i>Kuwait Ports Authority v Williams</i> [2024] UKPC 32	Dkt. 125, Ex. L	
JA-28	--	RX-75	<i>Gulf Investment Corp v The Port Fund LP</i> FSD 235 of 2019 and 13 of 2020, 19 June 2020	Dkt. 371, Ex. K	
JA-29	--	RX-169	McPherson & Keay's Law of Company Liquidation, 5th Ed. (excerpts)	Phillips Decl. B-50	
JA-30	--	RX-77	<i>FamilyMart China Holding Co Ltd (Respondent)</i> [2023] UKPC 33	Dkt. 125, Ex. EE	
JA-31	--	RX-78	<i>Re Free Rider Limited</i> [2010] 2 CILR 154	Dkt. 204, Ex. V	
JA-32	--	RX-133	Interpretation Act (1995 Revision)	Phillips Decl. Ex. B-01	
JA-33	--	RX-134	Companies Winding Up Rules (2023 Consolidation)	Phillips Decl. Ex. B-03	
JA-34	--	RX-135	Partnership Act (2025 Revision)		
JA-35	--	RX-136	Practice Direction No. 1 of 2018	Phillips Decl. Ex. B-07	
JA-36	--	RX-137	<i>Harrison v Tennant</i> (1856) 21 Beav 482	Phillips Decl. Ex. B-08	
JA-37	--	RX-138	<i>I.R.C. v Olive Mill Ltd</i> [1963] 1 WLR 712	Phillips Decl. Ex. B-09	

JOINT AUTHORITY	DEBTORS' AUTHORITY (DA)	RIGMORA AUTHORITY (RA)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS
JA-38	--	RX-139	<i>Ebrahimi v Westbourne Galleries</i> [1973] A.C. 360, HL	Phillips Decl. Ex. B-10	
JA-39	--	RX-140	<i>Bristol and West Building Society v Mothew</i> [1998] Ch. 1	Phillips Decl. Ex. B-11	
JA-40	--	RX-141	<i>Hurst v Bryk</i> [2002] 1 A.C. 185 (HL)	Phillips Decl. B-12	
JA-41	--	RX-142	<i>In Re Lehman Brothers International (Europe) (in administration) (No 2)</i> [2009] EWCA Civ 1161; [2010] Bus. L.R. 489	Phillips Decl. B-13	
JA-42	--	RX-143	<i>Belmont Park Investments Pty Ltd v BNY Corporate Trustee Services Ltd</i> [2011] UKSC 38; [2012] 1 A.C. 383	Phillips Decl. B-14	
JA-43	--	RX-144	<i>Certain Ltd. Partners in Henderson PFI Secondary Fund II LP v Henderson PFI Secondary Fund II LP</i> [2012] EWHC 3259 (Comm); [2013] Q.B. 934	Phillips Decl. B-15	
JA-44	--	RX-145	<i>Revenue and Customs Commissioners v Anson</i> [2013] EWCA Civ 63; [2013] S.T.C. 55	Phillips Decl. B-16	
JA-45	--	RX-146	<i>Re Pan Ocean Co Ltd</i> [2014] EWHC 2124 (Ch); [2014] Bus. L.R. 1041	Phillips Decl. B-17	
JA-46	--	RX-147	<i>Singularis Holdings v PricewaterhouseCoopers</i>	Phillips Decl. B-18	

JOINT AUTHORITY	DEBTORS' AUTHORITY (DA)	RIGMORA AUTHORITY (RA)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS
JA-47	--	RX-148	<i>MacDonald v Carnbroe Estates Ltd</i> [2019] UKSC 57; [2020] S.C. (UKSC) 23	Phillips Decl. B-19	
JA-48	--	RX-149	<i>Lau v Chu</i> [2020] UKPC 24; [2020] 1 WLR 4656	Phillips Decl. B-20	
JA-49	--	RX-150	<i>Re Sova Capital Ltd</i> [2023] EWHC 452 (Ch); [2024] 1 All E.R. (Comm) 69	Phillips Decl. B-21	
JA-50	--	RX-151	<i>Mitchell v Al Jaber</i> [2025] UKSC 43; [2025] 3 W.L.R. 849	Phillips Decl. B-22	
JA-51	--	RX-152	<i>Hopcraft v Close Brothers Ltd</i> [2025] UKSC 33; [2025] 3 W.L.R. 423	Phillips Decl. B-23	
JA-52	--	RX-153	<i>Re Core VCT Plc</i> [2025] EWHC 2316 (Ch)	Phillips Decl. B-24	
JA-53	--	RX-154	<i>In Re ICP Strategic Credit Income Fund Limited</i> [2014] 1 CILR 314	Phillips Decl. B-26	
JA-54	--	RX-155	<i>Arnage Holdings Ltd v Walkers</i> [2019] 2 CILR 382	Phillips Decl. B-27	
JA-55	--	RX-156	<i>In Re LATAM Finance Limited</i> [2020] 2 CILR 787	Phillips Decl. B-28	
JA-56	--	RX-157	<i>In Re Duet Estate Partners LP</i> [2020] (2) CILR 390	Phillips Decl. B-29	
JA-57	--	RX-158	<i>Tianrui (International) Holding Company Ltd v China Shanshui Cement Group Ltd</i> [2020] 1 CILR 417	Phillips Decl. B-30	

JOINT AUTHORITY	DEBTORS' AUTHORITY (DA)	RIGMORA AUTHORITY (RA)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS
JA-58	--	RX-159	<i>Re Padma Fund LP</i> [2021 (2) CILR 556]	Phillips Decl. B-31	
JA-59	--	RX-160	<i>Re ECM Straits Fund I LP FSD</i> 230 OF 2022 (RPJ), 20 December 2022	Phillips Decl. B-35	
JA-60	--	RX-161	<i>In Re Seahawk China Dynamic Fund</i> , KY 2022 GC 92, 9 August 2022	Phillips Decl. B-36	
JA-61	--	RX-162	<i>Re Rothenberg Ventures 2016 Feeder Fund LP</i> , KY 2024 GC 38, FSD 379 and 380 of 2023, 15 April 2024	Phillips Decl. B-38	
JA-62	--	RX-163	<i>Williams v Kuwait Ports Authority</i> , CICA (Civil) Appeal No 0011 of 2023, 15 August 2024	Phillips Decl. B-40	
JA-63	--	RX-164	<i>In Re ATP Life Science Ventures LP</i> [2025] CIGC (FSD) 106	Phillips Decl. B-43	
JA-64	--	RX-165	Goode on Principles of Corporate Insolvency Law, 5th Ed. (excerpts)	Phillips Decl. B-46	
JA-65	--	RX-166	Lewin on Trusts, 20th Ed. including First Supplement (excerpts)	Phillips Decl. B-47	
JA-66	--	RX-167	Lightman & Moss on The Law of Administrators and Receivers of Companies 6th. Ed. (excerpts)	Phillips Decl. B-48	
JA-67	--	RX-168	Lindley & Banks on Partnership, 21st Ed., incorporating First Supplement (excerpts)	Phillips Decl. B-49	

JOINT AUTHORITY	DEBTORS' AUTHORITY (DA)	RIGMORA AUTHORITY (RA)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS
JA-68	DX-66	--	Disclosure Statement, <i>In re Sea Launch Company, LLC</i> , No. 09-12153 (BLS) [Docket No. 796]		LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-69	DX-67	--	Second Amended Plan, <i>In re Sea Launch Company, LLC</i> , No. 09-12153 (BLS) [Docket No. 795]		LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-70	DA-22	--	<i>GPs Behaving Badly: Disputes Involving Cayman Exempted Limited Partnerships</i>		LPs: Object to the use of this client update to be treated as a legal authority.
JA-71	DA-23	--	<i>Schemes of Arrangement in the Cayman Islands</i>		LPs: Object to the use of this client update to be treated as a legal authority.
JA-72	DA-24	--	<i>Good News for Debtors Seeking Access to the Cayman Islands Restructuring Regime</i>		LPs: Object to the use of this client update to be treated as a legal authority.
JA-73	DA-25	--	<i>Cayman Islands Schemes of Arrangement Now Available for Exempted Limited Partnerships Using the Restructuring Officer Regime</i>		LPs: Object to the use of this client update to be treated as a legal authority.
JA-74	DX-2	RX-65	Judgment of Cayman Court, Dec. 22, 2025	Dkt. 117, Ex. F	
JA-75	--	RX-76	<i>Re ATP Life Since Ventures LP</i> [2025] CIGC (FSD) 106, Nov. 6, 2025 Judgment	Dkt. 125, Ex. E	
JA-76	--	RX-79	<i>Unicorn Biotech Ventures One Ltd v ATP III GP Ltd (No. 4)</i> [2025] CIGC (FSD) 124	Dkt. 125, Ex. F	
JA-77	--	RX-80	<i>Unicorn Biotech Ventures One Ltd v ATP III GP Ltd (No.3)</i>	Dkt. 371, Ex. A	

JOINT AUTHORITY	DEBTORS' AUTHORITY (DA)	RIGMORA AUTHORITY (RA)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS
			[2026] CIGC (FSD) 5 (Privilege Judgment)		
JA-78	DX-44	RX-88	Chancery Post-Trial Op., Dec. 5, 2025	Dkt. 125, Ex. H	

[Signature Page Follows]

Dated: March 4, 2026
Wilmington, Delaware

**RICHARDS, LAYTON &
FINGER, P.A.**

/s/ Clint M. Carlisle

John H. Knight (No. 3848)
Michael J. Merchant (No. 3854)
Daniel E. Kaprow (No. 6295)
Clint M. Carlisle (No. 7313)
Nicholas A. Franchi (No. 7401)
One Rodney Square
920 North King Street
Wilmington, DE 19801
Telephone: (302) 651-7700
Facsimile: (302) 651-7701
Email: knight@rlf.com
merchant@rlf.com
kaprow@rlf.com
carlisle@rlf.com
franchi@rlf.com

Respectfully Submitted,

DEBEVOISE & PLIMPTON LLP

Shannon Rose Selden (*admitted pro hac vice*)
M. Natasha Labovitz (*admitted pro hac vice*)
William H. Taft V (*admitted pro hac vice*)
Zachary H. Saltzman (*admitted pro hac vice*)
Natascha Born (*admitted pro hac vice*)
Carl Micarelli (*admitted pro hac vice*)
Sebastian Dutz (*admitted pro hac vice*)
66 Hudson Boulevard
New York, New York 10001
Telephone: (212) 909-6000
Email: srselden@debevoise.com
nlabovitz@debevoise.com
whtaft@debevoise.com
zsaltzman@debevoise.com
nborn@debevoise.com
cmicarelli@debevoise.com
spdutz@debevoise.com

Co-Counsel for Rigmora Biotech Investor One LP (by and through its general partner Unicorn Biotech Ventures One Ltd) and Rigmora Biotech Investor Two LP (by and through its general partner Unicorn Biotech Ventures Two Ltd)

EXHIBIT A

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:

Apple Tree Life Sciences, Inc., *et al.*,¹

Debtors.

Chapter 11

Case No. 25-12177 (LSS)

(Jointly Administered)

AMENDED JOINT EXHIBIT LIST FOR THE HEARING ON FEBRUARY 25, 2026

Parties in interest Rigmora Biotech Investor One LP, by its general partner Unicorn Biotech Ventures One Ltd, and Rigmora Biotech Investor Two LP, by its general partner Unicorn Biotech Ventures Two Ltd (collectively, the “**LPs**”), and the above-captioned debtors and debtors in possession (the “**Debtors**,” and with the LPs, the “**Parties**”) by and through their undersigned counsel, hereby provide this joint exhibit list (the “**Exhibit List**”) identifying the exhibits the Parties ~~may~~ ~~introduce~~ introduced into evidence in connection with the *Motion of Rigmora Biotech Investor One LP and Rigmora Biotech Investor Two LP for Relief from the Automatic Stay* [Dkt. 125]; and the *Amended Motion of Rigmora Biotech Investor One LP and Rigmora Biotech Investor Two LP for an Order Dismissing the Bankruptcy Cases of ATP Life Science Ventures L.P. and ATP III GP, Ltd.* [Dkt. 204] ~~to~~ ~~be~~ heard at the hearing scheduled on February 25, 2026 at 10:00 a.m. (ET) (the “**Hearing**”) before the Honorable Laurie S. Silverstein, at the United States Bankruptcy Court for the District of Delaware, 824 N. Market Street, 6th Floor, Courtroom No. 2, Wilmington, Delaware 19801. Attached as Exhibit A is a redline against the parties’ joint exhibit list filed on February 25, 2026.

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors’ service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

February 25 ~~March 4~~, 2026**EXHIBITS**

The Parties identify the following exhibits ~~that may be used at the Hearing~~ admitted in connection with the matters to be heard. The Parties reserve the right to ask the Court to take judicial notice of pleadings, transcripts, and/or documents filed in or in connection with the above-captioned cases, ~~to offer rebuttal exhibits, and to modify, supplement, or amend this Exhibit List at any time prior to or during the Hearing.~~ ~~Designation of any exhibit below does not waive any objections the Parties may have to any exhibit listed on any Party's exhibit list or introduced at the hearing.~~ The parties have met and conferred concerning the exhibits highlighted in yellow but have not been able to reach agreement as to the introduction of those exhibits into the record.

JOINT EXHIBIT	DEBTORS' EXHIBIT (DX)	RIGMORA EXHIBIT (RX)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS	<u>ENTERED IN EVIDENCE</u>
JX-0	DX-5	RX-0	First Amended and Restated Limited Partnership Agreement ("LPA")	ATP_00202247		<u>2/25 Tr. 81:20-82:1</u>
JX-1	<u>==</u>	RX-1	LPA Amendment No. 1	ATP_00202344		<u>2/25 Tr. 81:20-82:1</u>
JX-2	DX-18	RX-2	LPA Amendment No. 2	ATP_00202349		<u>2/25 Tr. 81:20-82:1</u>
JX-3	DX-19	RX-3	LPA Amendment No. 3	ATP_00202357		<u>2/25 Tr. 81:20-82:1</u>
JX-4	DX-20	RX-4	LPA Amendment No. 4	ATP_00202362		<u>2/25 Tr. 81:20-82:1</u>
JX-5	DX-21	RX-5	LPA Amendment No. 5	ATP_00202365		<u>2/25 Tr. 81:20-82:1</u>
JX-6	DX-22	RX-6	LPA Amendment No. 6	ATP_00202375		<u>2/25 Tr. 81:20-82:1</u>

~~February 25~~ March 4, 2026

JX-7	DX-23	RX-7	LPA Amendment No. 7	ATP_00202378		2/25 Tr. 81:20-82:1
JX-8	DX-24	RX-8	LPA Amendment No. 8	ATP_00202383		2/25 Tr. 81:20-82:1
JX-9	DX-25	RX-9	LPA Amendment No. 9	ATP_00202388		2/25 Tr. 81:20-82:1
JX-10	DX-26	RX-10	LPA Amendment No. 10	ATP_00202407		2/25 Tr. 81:20-82:1
JX-11	DX-27	RX-11	LPA Amendment No. 11	ATP_00202412		2/25 Tr. 81:20-82:1
JX-12	DX-28	RX-12	LPA Amendment No. 12	ATP_00202416		2/25 Tr. 81:20-82:1
JX-13	DX-29	RX-13	LPA Amendment No. 13	ATP_00202424		2/25 Tr. 81:20-82:1
JX-14	DX-30	RX-14	LPA Amendment No. 14	ATP_00202429		2/25 Tr. 81:20-82:1
JX-15	DX-31	RX-15	LPA Amendment No. 15	ATP_00202437		2/25 Tr. 81:20-82:1
JX-16	DX-32	RX-16	LPA Amendment No. 16	ATP_00202440		2/25 Tr. 81:20-82:1
JX-17	DX-33	RX-17	LPA Amendment No. 17	ATP_00202444		2/25 Tr. 81:20-82:1
JX-18	DX-34	RX-18	LPA Amendment No. 18	ATP_00202461		2/25 Tr. 81:20-82:1
JX-19	DX-35	RX-19	LPA Amendment No. 19	ATP_00202477		2/25 Tr. 81:20-82:1
JX-20	DX-36	RX-20	LPA Amendment No. 20	ATP_00260368		2/25 Tr. 81:20-82:1
JX-21	DX-37	RX-21	LPA Amendment No. 21	ATP_00202482		2/25 Tr. 81:20-82:1
JX-22	DX-38	RX-22	LPA Amendment No. 22	ATP_00202487		2/25 Tr. 81:20-82:1

February 25 ~~March 4~~, 2026

JX-23	DX-15	RX-23	Nine Square Therapeutics, Inc. Series A Preferred Stock Purchase Agreement	ATP_00001600		2/25 Tr. 237:4-238:19
JX-24	DX-12	RX-24	Initial (Opal Biosciences, Inc) Series A Preferred Stock Purchase Agreement	ATP_00001104		2/25 Tr. 237:4-238:19
JX-25	DX-14	RX-25	Nereid Therapeutics Inc. Preferred Stock Purchase Agreement	ATP_00001242		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-26	DX-10	RX-26	Aulos Biosciences, Inc. Series A Preferred Stock Purchase Agreement	ATP_00000678		2/25 Tr. 237:4-238:19
JX-27	DX-13	RX-27	Apertor Pharmaceuticals, Inc Series A Preferred Stock Purchase Agreement	ATP_00000627		2/25 Tr. 237:4-238:19
JX-28	DX-1	RX-28	Marlinspike Therapeutics Inc. Series A Preferred Stock Purchase Agreement	ATP_00334406		2/25 Tr. 237:4-238:19
JX-29	DX-11	RX-29	Evercrisp Biosciences, Inc. Series A Preferred Stock Purchase Agreement	ATP_00334675		2/25 Tr. 237:4-238:19
JX-30	DX-16	RX-30	Red Queen Therapeutics Inc Series A Preferred Stock Purchase Agreement	ATP_00001669		2/25 Tr. 237:4-238:19
JX-31	DX-8	RX-31	Aethon Therapeutics, Inc. Series A Preferred Stock Purchase Agreement	ATP_00000546		2/25 Tr. 237:4-238:19
JX-32	==	RX-32	Deep Apple Therapeutics, Inc. Series A Preferred Stock Purchase Agreement	ATP_00088318		2/25 Tr. 237:4-238:19
JX-33	==	RX-33	Ascidian Therapeutics, Inc. Series A Preferred Stock Purchase Agreement	ATP_00322023		2/25 Tr. 237:4-238:19
JX-34	==	RX-34	Marengo Therapeutics, Inc. Series B Preferred Stock	ATP_00284891		2/25 Tr. 237:4-238:19

February 25 ~~March 4~~, 2026

			Purchase Agreement			
JX-35	==	RX-35	Replicate Bioscience, Inc. Series A Preferred Stock Purchase Agreement	ATPBK_00016512		2/25 Tr. 237:4-238:19
JX-36		RX-36	Apple Tree Life Sciences, Inc. ("ATLS") Chapter 11 Petition	Dkt. 1-		
JX-37	==	RX-37	ATP Life Sciences Ventures L.P., Chapter 11 Petition	Dkt. 1 (Case No. 25-12178)		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-38	==	RX-38	ATP III GP, Ltd., Chapter 11 Petition	Dkt. 1 (Case No. 25-12179)		2/26 Tr. 161:20-24
JX-39		RX-39	Apertor Pharmaceuticals, Inc., Chapter 11 Petition	Dkt. 1 (Case No. 25-12201)		
JX-40		RX-40	Initial Therapeutics, Inc., Chapter 11 Petition	Dkt. 1 (Case No. 25-12202)		
JX-41		RX-41	Marlinspike Therapeutics, Inc., Chapter 11 Petition	Dkt. 1 (Case No. 25-12203)		
JX-42		RX-42	Red Queen Therapeutics, Inc., Chapter 11 Petition	Dkt. 1 (Case No. 25-12204-LSS)		
JX-43		RX-43	Evererisp Biosciences, Inc., Chapter 11 Petition	Dkt. 1 (Case No. 26-10000)		
JX-44		RX-44	Nereid Therapeutics Inc., Chapter 11 Petition	Dkt. 1 (Case No. 26-10048)		
JX-45		RX-45	Nine Square Therapeutics, Inc., Chapter 11 Petition	Dkt. 1 (Case No. 26-10001)		
JX-46		RX-46	Intergalactic Chapter 11 Petition, Dec. 19, 2023	Dkt. 371, Ex. O		
JX-47		RX-47	Apple Tree Life Sciences, Inc. ("ATLS") Schedule of Assets and Liabilities	Dkt. 236-		
JX-48		RX-48	Apple Tree Life Sciences, Inc. ("ATLS") Statement of	Dkt. 237-		

February 25 ~~March 4~~, 2026

			Financial Affairs			
JX-49	==	RX-49	ATP III GP, Ltd., Schedule of Assets and Liabilities	Dkt. 241		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-50	==	RX-50	ATP III GP, Ltd., Statement of Financial Affairs	Dkt. 242		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-51	==	RX-51	ATP Life Science Ventures, L.P., Schedule of Assets and Liabilities	Dkt. 238		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-52	==	RX-52	ATP Life Science Ventures, L.P., Statement of Financial Affairs	Dkt. 240		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-53	DX-39	RX-53	Status Conference Hearing Transcript, December 15, 2025			
JX-54	DX-40	RX-54	First Day Hearing Transcript, December 17, 2025			
JX-55	DX-41		December 30, 2025 Hearing Transcript	Docket No. 113		
JX-56	DX-42	RX-55	Second Day Hearing Transcript, Jan. 20, 2026			
JX-57	DX-43		February 13, 2026 Discovery Conference Transcript			
JX-58	==	RX-56	Funding and DIP Motion Hearing Transcript, February 19, 2026			2/25 Tr. 238:1-17
JX-59		RX-57	Funding and DIP Motion Hearing Transcript, February 20, 2026			

February 25 ~~March 4~~, 2026

JX-60	DX-50		Writ of Summons, Cause No. FSD 2025-0146, dated June 2, 2025	JX-1416 in-Chancery	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein
JX-61	DX-51		Ex parte summons Cause No. FSD 2025-0146, dated June 12, 2025	JX-1434 in-Chancery	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein
JX-62	==	RX-58	Cayman Winding Up Petition	Dkt. 125, Ex. P	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein The Parties stipulate that this joint exhibit be admitted into evidence.
JX-63	DX-1	RX-59	Cayman Amended Winding-Up Petition, Nov. 21, 2025	Dkt. 125, Ex. B	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein The Parties stipulate that this joint exhibit be admitted into evidence.
JX-64	==	RX-60	Cayman Amended Defence to Winding-Up Petition, Nov. 17, 2025	Dkt. 125, Ex. BB	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein The Parties stipulate that this joint exhibit be admitted into evidence.
JX-65	DX-48	==	<i>Rigmora's Amended Reply to the Amended Defense to the Amended Winding Up Petition</i> , dated November 24, 2025		The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein The Parties stipulate that this joint exhibit be admitted into evidence.
JX-66	==	RX-61	Cayman PTR Tr., Dec. 17, 2025	Dkt. 125, Ex. AA	The Parties stipulate that this joint exhibit be admitted into evidence.
JX-67		RX-62	Cayman Hr'g Tr., Oct. 31, 2025	Dkt. 125, Ex. Q	

February 25 March 4, 2026

JX-68	DX-49	RX-63	Petitioners' Cayman Skeleton Argument, Dec. 16, 2025	Dkt. 125, Ex. R	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein	The Parties stipulate that this joint exhibit be admitted into evidence.
JX-69	==	RX-170	2025.12.17 Procedural Trial Scheduling Order			The Parties stipulate that this joint exhibit be admitted into evidence.
JX-70		RX-64	Cayman Hr'g Tr., Aug. 1, 2025	Dkt. 125, Ex. S		
JX-71	DX-2	RX-65	Judgment of Cayman Court, Dec. 22, 2025	Dkt. 117, Ex. F		
JX-72		RX-76	Re ATP Life Since Ventures LP [2025] CIGC (FSD) 106, Nov. 6, 2025 Judgment	Dkt. 125, Ex. E		
JX-73		RX-79	Unicorn Biotech Ventures One Ltd v ATP III GP Ltd (No. 40 [2025] CIGC (FSD) 124	Dkt. 125, Ex. F		
JX-74		RX-80	Unicorn Biotech Ventures One Ltd v ATP III GP Ltd (No. 3) [2026] CIGC (FSD) 5 (Privilege Judgment)	Dkt. 371, Ex. A		
JX-75		RX-81	Verified Chancery Court Complaint		The parties agree that pleadings from the Chancery case shall not be taken as truth of the matters asserted therein	
JX-76		RX-82	Chancery Pre-Trial Order, Sept. 5, 2025	Dkt. 125, Ex. G		
JX-77		RX-83	Chancery Letter Decision Resolving Plaintiffs' Exceptions, Sept. 8, 2025	Dkt. 371, Ex. L		
JX-78		RX-84	Chancery Court Pre-Trial Conf. Tr., Sept. 11, 2025			

JX-79	DX-63		September 19, 2025, Hearing Transcript, ATP III GP, LTD. v. Rigmora, No. 2025-0607-KSJM	Docket No. 141-1, Ex. B	
JX-80		RX-85	Chancery Trial Tr. Oct. 16-17, 2025	Dkt. 125, Ex. I	
JX-81		RX-86	Chancery Court Status Quo Motion Hr'g Tr., Oct. 21, 2025		
JX-82		RX-87	Chancery Post-Trial Arg. Tr., Nov. 21, 2025	Dkt. 125, Ex. V	
JX-83	DX-44	RX-88	Chancery Post-Trial Op., Dec. 5, 2025	Dkt. 125, Ex. H	
JX-84	DX-45	RX-89	Chancery Partial Final Judgment and Order Pursuant to Rule 54(b), Dec. 11, 2025	Dkt. 125, Ex. FF	
JX-85		RX-90	Correspondence GP Letter to Chancery Court, Dec. 11, 2025	Dkt. 125, DD	
JX-86		RX-91	Correspondence from D. Kaprow, Dec. 8, 2025	Dkt. 125, Ex. W	
JX-87	DX-46	RX-92	Email from D. Kaprow to Quinn Emanuel attaching proposed form of order, Dec. 8, 2025	RIGMORA_BK00 000143	2/25 Tr. 41-42
JX-88		RX-93	Email correspondence between D. Kaprow and A. Berdon re proposed form of order, Dec. 9, 2025	RIGMORA_BK00 000148	
JX-89		RX-94	Email from A. Berdon, Dec. 10, 2025	Dkt. 125, Ex. X	
JX-90	DX-47		Email from Rigmora's Counsel to Debtors' Counsel Regarding	RIGMORA_BK17 9-RIGMORA_BK 192	

			Proposed Form of Chancery Court Order, with Attachments, dated December 10, 2025		
JX-91		RX-95	LPs' Proposed Implementing Order, Dec. 10, 2025	Dkt. 371, Ex. H	
JX-92		RX-96	GP Proposed Chancery Order, Dec. 10, 2025	Dkt. 371, Ex. I	
JX-93		RX-97	Correspondence from A. Berdon, Dec. 22, 2025	Dkt. 125, Ex. Y	
JX-94		RX-98	Correspondence to Cayman Court, Dec. 10, 2025	Dkt. 125, Ex. Z	
JX-95		RX-99	January 2026 Correspondence between LPs and Debtors re- Document Production	Dkt. 371, Ex. M	
JX-96		RX-102	B. Riley Retention App.	Dkt. 131	
JX-97		RX-103	Declaration of Mark Phillips KC	Dkt. 126	Debtors: Hearsay
JX-98		RX-104	Declaration of Liam Faulkner	Dkt. 4	Debtors: Hearsay
JX-99	==	RX-105	Declaration of Ilya Strebulaev	Dkt. 365	Debtors: Hearsay The parties stipulate that sections III and V of this joint exhibit be admitted into evidence.
JX-100		RX-106	Amended Declaration of Brandon Aebersold	Dkt. 369	Debtors: Hearsay
JX-101		RX-107	Correspondence between P. Mandarino and B. Riley, Dec. 8, 2025	ATPBK_0003505 +	
JX-102		RX-108	Email from P. Mandarino to	ATPBK_0003501	

February 25 March 4, 2026

			B. Riley, Dec. 8, 2025	8	
JX-103		RX-109	B. Riley Draft Engagement Letter, Dec. 6 2025	ATPBK_00034992	
JX-104		RX-110	B. Riley Engagement Letter December 8	APBK_000034992	
JX-105		RX-111	B. Riley Engagement Letter Dec 9	Dkt. 131-3	
JX-106	=	RX-112	Email from S. Harrison to Y. Bogdanov, May 11, 2025	RIGMORA00062977	The Parties stipulate that this joint exhibit be admitted into evidence.
JX-107		RX-113	Correspondence between Y. Bogdanov and S. Harrison, June 11, 2025	ATPBK_00038495	
JX-108		RX-114	Email from S. Harrison to J. Yanchik, Dec. 7, 2025	ATPBK_00048613	
JX-109		RX-115	Correspondence between S. Harrison and A. Hack, July 2025	ATPBK_00023442	
JX-110		RX-116	Correspondence between S. Harrison and T. Hirsch, October 5 2025	ATPBK_00005983	
JX-111		RX-117	Correspondence between S. Harrison and T. Hirsch, October 6 2025	ATPBK_00005624	
JX-112	DX-3	RX-118	Grant Thornton 2024 Audited Financials	ATP_00089374	2/26 Tr. 146:3-11
JX-113		RX-119	March 2025 SPV Deck	ATPBK_00018226	LPs: object to the extent offered for truth of statements therein
JX-114		RX-120	October 2025 Portfolio Lift Out Deck	ATP_00480811	LPs: object to the extent offered for truth of statements therein
JX-115	=	RX-121	2024 ATP LSV Financial Statements	ATP_00000253	2/26 Tr. 179-180
JX-116	DX-64	RX-122	December 2025 Portfolio		LPs: object to the The Parties stipulate

February 25 ~~March 4~~, 2026

			Lift Out Deck		extent offered for truth of statements therein <u>This exhibit will be submitted under seal at Debtors' request due to confidentiality considerations, with a sealing motion to follow.</u>	<u>that this joint exhibit be admitted into evidence, subject to the LPs' objection that statements therein should not be taken for the truth of the matter asserted.</u>
JX-117	DX-65		Lift Out Presentation	ATPBK_0002611-1-	LPs: object to the extent offered for truth of statements therein	
JX-118		RX-123	Demonstrative—Debtors' Resp. to Interrogatory 8	Harrison Ex. 6		
JX-119		RX-124	Demonstrative—Reported Commitments	Harrison Ex. 10		
JX-120	=	RX-125	Debtors' DIP Funding Motion & DIP Term Sheet, 13 Feb. 2026	Dkt. 313	LPs: assertions in DIP Funding Motion not to be taken for truth of the matter asserted	<u>2/26 Tr. 55:2-10</u>
JX-121		RX-126	DIP Facility Term Sheet (Rigmora)	Harrison Ex. 23		
JX-122		RX-127	Debtors' Responses and Objections to First Set of Requests for Production and Interrogatories, January 3, 2026			
JX-123	=	RX-128	Debtors' Responses and Objections to Second Set of Requests for Production and Interrogatories, February 2, 2026			<u>The Parties stipulate that this joint exhibit be admitted into evidence.</u>
JX-124		RX-129	Debtors' Supplemental Responses & Objections to LPs' Second Funding			

February 25 ~~March 4~~, 2026

			Motion RFPs and Interrogatories, February 2026		
JX-125	=	RX-130	Debtors' Supplemental Responses and Objections to Second Set of Requests for Production and Interrogatories, February 16, 2026		The Parties stipulate that this joint exhibit be admitted into evidence.
JX-126		RX-131	Plaintiff's Responses and Objections to Defendants' Second Set of Interrogatories, July 22, 2025, Chancery Litigation		
JX-127		RX-132	December 9, 2025 Letter from Walkers to Campbells		
JX-128		RX-173	Rigmora LP's designation of Timothy Pohl's deposition		
JX-129	DX-4		Debtor's First Request for Production of Documents	Docket No. 245-2	LPs: Relevance; Completeness (should include LPs' Responses & Objections)
JX-130	DX-6		Apertor Pharmaceuticals, Inc. Secured Promissory Note, dated June 11, 2025	Docket No. 245-8	
JX-131	DX-7	=	Parent Pledge Agreement, dated 2023	Docket No. 245-9	LPs: Relevance 3/3 – Debtors propose stipulating into evidence
JX-132	DX-52	=	Email from Daniel Finkelman to Yuri Bogdanov, et al., with attachments Regarding Second Amendment to Loan Agreement, dated between March 9 and June 11, 2025	ATPBK_0006437 3-ATPBK_00064399	LPs: Hearsay; Relevance 3/3 – Debtors propose stipulating into evidence
JX-133	DX-53	=	Email from Patrik Blochlinger to Daniel	ATPBK_0006440 0-ATPBK_000644	LPs: Hearsay; Relevance 3/3 – Debtors propose stipulating into

			<i>Finkelman, et al. Regarding Second Amendment to Loan Agreement, dated between March 9 and June 11, 2025</i>	17		evidence
JX-134	DX-54		<i>Order Authorizing the Debtors to Open New Segregated Bank Account</i>	Docket No. 79		
JX-135	DX-55		<i>Designations of Deposition Transcript of Yuri Bogdanov, conducted on February 15, 2026</i>			LPs: object to the extent designations used when Mr. Bogdanov available for live testimony Debtors: same designations as for 2/19 hearing subject to rights to use other portions for impeachment during cross examination
JX-136	DX-56		<i>Nereid Therapeutics Incorporated Secured Promissory Note, dated June 11, 2025</i>	Docket _____ No. 144-17; _____ Docket No. 228-2		
JX-137	DX-57		<i>Secured Promissory Note between Apertor and ATP, dated June 11, 2025</i>	Docket No. 144-13		
JX-138	DX-58		<i>Secured Promissory Note between Evercrisp and ATP, dated June 11, 2025</i>	Docket No. 144-14		
JX-139	DX-59		<i>Secured Promissory Note between Initial and ATP, dated June 11, 2025</i>	Docket No. 89-3		
JX-140	DX-60		<i>First Amendment to Secured Promissory Note between Initial and ATP, dated July 24, 2025</i>	Docket No. 144-15		
JX-141	DX-61		<i>Secured Promissory Note between Marlinspike and ATP, dated June 11, 2025</i>	Docket No. 144-16		
JX-142	DX-62		<i>Secured Promissory Note between Nine Square and</i>	Docket No. 144-18		

February 25 ~~March~~ 4, 2026

			ATP, dated June 11, 2025			
JX-143	<u>==</u>	RX-174	Q3 2025 ATP Fund Digest	ATPBK_0000663 1		<u>The Parties stipulate that this joint exhibit be admitted into evidence.</u>
JX-144	<u>==</u>	RX-175	Q4 2025 ATP Fund Digest			<u>2/26 Tr. 117:12-22</u>
JX-145		RX-176	Email from S. Harrison to D. Finkelman dated October 18, 2023	ATP_00462660		Debtors: Privilege. These items were produced to Rigmora on the basis that Rigmora was within the attorney-client privilege at the time. The Debtors assert that Rigmora cannot waive the privilege.
JX-146		RX-177	Email from D. Finkelman to S. Harrison dated October 18, 2023 (with attachment "Restructuring.docx")	ATP_00464242		Debtors: Privilege. These items were produced to Rigmora on the basis that Rigmora was within the attorney-client privilege at the time. The Debtors assert that Rigmora cannot waive the privilege.
JX-147	<u>==</u>	RX-178	Aulos Series A-1 Stock Purchase Agreement (January 24, 2025 Closing)	ATP_00000710		<u>2/25 Tr. 237:4-238:19</u>
JX-148	<u>==</u>	RX-179	Replicate Stock Purchase Agreement (inclusive of all tranches)	ATP_00310825		<u>2/25 Tr. 237:4-238:19</u>
JX-149	<u>==</u>	RX-180	Elstar Series A SPA	GT_0001616		<u>2/25 Tr. 237:4-238:19</u>
JX-150	<u>==</u>	RX-181	Galvanize Series B SPA	ATP_00219040		<u>2/25 Tr. 237:4-238:19</u>
JX-151	<u>==</u>	RX-182	Galvanize Series C SPA	ATP_00409203		<u>The Parties stipulate that this joint exhibit be admitted into evidence.</u>
JX-152	<u>==</u>	RX-183	Limelight Series A2 SPA	ATP_00196274		<u>The Parties stipulate that this joint exhibit be admitted into evidence.</u>

February 25 March 4, 2026

JX-153		RX-184	LPs' Additional Deposition Designations for 2/25 Hearing (Jardine 30(b)(6); Finkelman, Chancery)		Debtors: Reserve the right to review and counterdesignate.
JX-154		RX-185	Granted Case Schedule	Chancery Dkt. 54	
JX-155		RX-186	Cayman Case FSD-2025-0151, Consent Order for Directions (Trial), November 20, 2025		
JX-156		RX-187	Summons (Stay of Winding Up Petition), FSD-151 of 2025, June 26, 2025		
JX-157		RX-188	Cayman Injunction Order, June 20, 2025		
JX-158		RX-189	Cayman Case Schedule, August 20, 2025		
JX-159		RX-190	Privilege Summons, FSD-151 of 2025, October 2, 2025		
JX-160		RX-191	Email from Cayman Court to Campbells and Walkers dated December 1, 2025 issuing privilege decision		
JX-161	==	RX-192	Letter from Walkers to Campbells, September 8, 2025		<u>The Parties stipulate that this joint exhibit be admitted into evidence.</u>
JX-162		RX-193	Email from Walkers to Cayman Court dated December 8, 2025 re appeal of privilege decision		
JX-163		RX-194	B. Riley Engagement Letter, December 4, 2025	ATPBK_0003503 0	
JX-164		RX-195	WhatsApp between	ATP-00200288	

February 25 March 4, 2026

			Yanchik and Ehlers, August 20, 2024		
JX-165		RX-196	Email from S. Harrison re Interim Funding, July 18, 2025	RIGMORA_BK00002272	
JX-166		RX-197	Email exchange between Engels and Castellano, May 17, 2022	ATP_00108700	Debtors: Privilege. These items were produced to Rigmora on the basis that Rigmora was within the attorney-client privilege at the time. The Debtors assert that Rigmora cannot waive the privilege.
JX-167		RX-198	WhatsApp between Harrison and Ehlers, August 20, 2024	ATP-00272602	
JX-168		RX-199	Email from D. Kaprow re proposed implementing order	RIGMORA_BK00000143	
JX-169		RX-200	Email from M. Ye to Y. Bogdanov, December 12, 2024, attaching Amendment 22 and Braeburn settlement documents	RIGMORA00007617	Debtors: Reserve the right to review the full document sought to be admitted. Bates number references on the settlement document.
JX-170		RX-201	Email from Y. Bogdanov to Y. Yakovlev, A. Milkov, Z. Iskhakov, December 24, 2024, attaching budget requests	RIGMORA000069663	
JX-171	<u>==</u>	RX-202	Emails from Bogdanov to Harrison re: capital calls	RIGMORA_BK00002643	2/25 Tr. 34:11-18
JX-172	<u>==</u>	RX-203	Q2 2025 ATP Fund Digest		2/26 Tr. 117:6-10
JX-173	DX-68	<u>==</u>	<i>Email Between Anna Batarina and Anna Kolonchina Regarding New Deal Documentation for Apertor, dated</i>	Chancery JX0114	<u>LPs: Hearsay; Relevance</u> 3/3 – Debtors propose stipulating into evidence

			October 16, 2020, with Attachments			
JX-174	DX-69		Email Between Anna Batarina and Anna Kolonchina Regarding Replicate Budget and CFIUS Memos, dated January 14, 2021, with Attachments	Chancery JX0150		
JX-175	DX-70	=	Email Between Anna Batarina and Anna Kolonchina Regarding Evercrisp Investment Memorandum, CFIUS Memo, Budget and Capital Call, dated July 23, 2021, with Attachments	Chancery JX0243	<u>LPs: Hearsay; Relevance</u>	<u>3/3 – Debtors propose stipulating into evidence</u>
JX-176	DX-71	=	Email Between Anna Batarina and Anna Kolonchina Regarding Red Queen Investment Memorandum, CFIUS Memo, Budget and Capital Call, dated September 29, 2021, with Attachments	Chancery JX0269	<u>LPs: Hearsay; Relevance</u>	<u>3/3 – Debtors propose stipulating into evidence</u>
JX-177	DX-72		Email Between Anna Batarina and Anna Kolonchina Regarding Deep Apple Investment Memorandum, CFIUS Memo, Budget and	Chancery JX0310		

			Capital Call, dated December 11, 2021, with Attachments		
JX-178	DX-73	=	Email Between Anna Batarina and Anna Kolonchina Regarding Marlinspike Investment Memorandum, CFIUS Memo, Budget and Capital Call, dated December 14, 2021, with Attachments	Chancery JX0312	<u>LPs: Hearsay; Relevance</u> <u>3/3 – Debtors propose stipulating into evidence</u>
JX-179	DX-74		Email Between Anna Batarina and Anna Kolonchina Regarding Aethon Investment Memorandum, CFIUS Memo, Budget and Capital Call, dated November 23, 2022, with Attachments	Chancery JX0470	
JX-180	DX-75		Email Between Patrik Bloehlinger and Zufar Iskhakov and Andrey Milkov Regarding Deep Apple Investment Memorandum, CFIUS Memo, Budget and Capital Call, dated November 23, 2022, with Attachments	Chancery JX1216	
JX-181	DX-76		Statement by the General Partner for Registration	—	

			as an Exempted Limited Partnership Pursuant to Section 91(1) of the Exempted Limited Partnership Law, dated October 29, 2012		
JX-182	DX-77		Certificate of Registration of Exempted Limited Partnership, dated October 29, 2012	--	
JX-183	DX-78		Certificate of Change of Name of an Exempted Limited Partnership, dated November 30, 2020	--	
JX-184	DX-79		Apple Tree Partners IV, L.P. Statement by the General Partner of a Change in the Registered Particulars of an Exempted Limited Partnership, dated November 30, 2020	--	
JX-185	DX-80		Winding Up Petition, Cause No. FSD-2025-0151, dated June 6, 2025	--	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein
JX-186	DX-81		Amended Ex Parte Summons, Cause No. FSD-2025-0146, dated June 18, 2025	--	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein
JX-187	DX-82	==	Ex Parte Injunction Order, Cause No. FSD 2025-0146, dated June	--	The parties agree that pleadings from the Cayman case shall not be taken as truth of the The Parties stipulate that this joint exhibit be admitted into evidence.

			20, 2025		matters asserted therein	
JX-188	DX-83	==	<i>Summons to Appoint Joint Provisional Liquidators</i> , Cause No. FSD 2025-0151, dated September 17, 2025	--	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein	<u>The Parties stipulate that this joint exhibit be admitted into evidence.</u>
JX-189	DX-84		<i>Amended Summons to Appoint Joint Provisional Liquidators</i>, Cause No. FSD 2025-0151, dated September 24, 2025	--	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein	
JX-190	DX-85		<i>Amended Winding Up Petition</i>, Cause No. FSD 2025-0151, dated November 21, 2025	--	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein	
JX-191	DX-86		<i>Amended Writ of Summons</i>, Cause No. FSD 2025-0146, dated November 21, 2025	--	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein	
JX-192	DX-87		<i>Letter from Campbells LLP to Walkers (Cayman) LLP</i>, dated September 10, 2025	--		
JX-193	DX-88		<i>Plaintiffs' /Petitioners' Skeleton Argument for the CMC on 31 October 2025</i>, Cause No. FSD 2025-0151	--	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein	
JX-194	DX-89		<i>Transcript of 31 October 2025 CMC Hearing</i>, Cause No. FSD 2025-0151	--	The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein	

February 25 ~~March 4~~, 2026

JX-195	DX-90		LP Funding Proposal, dated February 23, 2026	—		
JX-196	DX-91		First Affidavit of Yuri Bogdanov, Cause No. FSD 2025-0146, dated June 12, 2025	---		The parties agree that pleadings from the Cayman case shall not be taken as truth of the matters asserted therein
JX-197	DX-92		Email from Yuri Bogdanov Regarding Liquidity Crisis, dated October 9, 2022	Chancery JX444		
JX-198	DX-93		Email from Yuri Bogdanov Regarding Liquidity Crisis, dated October 11, 2022	Chancery JX446		
JX-199	DX-94	==	Email from Yuri Bogdanov Regarding Liquidity Crisis, dated November 10, 2022	Chancery JX463		2/25 Tr. 53:3-18
JX-200	DX-95	==	Email from Yuri Bogdanov to Seth Harrison, dated May 15, 2025	Chancery JX1318		2/25 Tr. 56:5-11
JX-201	DX-96	==	Deep Apple Press Release, dated June 11, 2025	Chancery JX1428	LPs: object to the extent offered for truth of statements therein	2/25 Tr. 63:7-24 (admitted for limited purpose of the fact that it publicly announces and discusses transaction)
JX-202-22 8	DX-97-123	==	RTW Presentation, dated November 20, 2025, ATP Fund Digest	—	LPs: Relevance	The Parties stipulate that this joint exhibit be admitted into evidence.
JX-203-22 9	DX-98-124	==	RTW Presentation, dated December 18, 2025 Email	ATP_00361287	LPs: Relevance	2/26 Tr. 105-107 (admitted for limited

February 25 March 4, 2026

			from J. Trenkle (Novo) to S. Harrison dated November 19, 2023			purposes in light of hearsay objection)
JX-204-23 0	DX-99-	RX-204	Email from Dan Finkelman to Second Witness Statement of Dr. Seth Harrison Regarding Sanctions Memo, (Trial Statement), Cause FSD 146 of 2025 (Cayman Proceedings) dated February 7 December 8, 2024 2025	Chancery JX786		The Parties stipulate that this joint exhibit be admitted into evidence subject to hearsay rules and exceptions.
JX-205-23 1	DX-100-125	==	Email from Andrew Berdon to David Beller Emails Regarding Chancery Litigation Evercrisp Capital Call, dated June 2 January 23, 2025	Chancery JX-1153	LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026	3/3 – Debtors propose stipulating into evidence
JX-206-23 2	DX-101-126	==	Email from William Taft to Shannon Doughty Emails Regarding Chancery Litigation Aethon and Marlinspike Budgets, dated June 3 July 2, 2025 2024	ATP 00123898	LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026	3/3 – Debtors propose stipulating into evidence
JX-207-23 3	DX-102-127	==	Email from Daniel Kaprow to Michael Barlow Emails Regarding Chancery Litigation Portfolio Company Budgets, dated June 4 July 3, 2025 2024	ATP 00143664	LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026	3/3 – Debtors propose stipulating into evidence
JX-208-23 4	DX-103-128	==	Email from Chancery Court to Michael Barlow Emails	ATP 00083128	LPs: Hearsay, Relevance; unduly	3/3 – Debtors propose stipulating into

			<i>Regarding Status-Conference Deep Apple Capital Call, dated June 5 July 30, 2025 2024</i>		<u>prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026</u>	<u>evidence</u>
JX 209 -23 <u>5</u>	DX 104 -129	=	<i>Email from Michael Barlow to Daniel Kaprow Emails Regarding Chancery Litigation Evercrisp Capital Calls, dated June 5 August 19, 2025 2024</i>	<u>ATP_00082118</u>	<u>LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026</u>	<u>3/3 – Debtors propose stipulating into evidence</u>
JX 210 -23 <u>6</u>	DX 105 -130	=	<i>Email from Michael Barlow to Blake Rohrbacher Emails Regarding Chancery Litigation, dated September 12, 2025 Deep Apple Capital Calls, dated October 17, 2024</i>	<u>ATP_00453257</u>	<u>LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026</u>	<u>3/3 – Debtors propose stipulating into evidence</u>
JX 211 -23 <u>7</u>	DX 106 -131	=	<i>Email from Michael Barlow to Daniel Kaprow Emails Regarding Motion to Expedite Deep Apple Capital Call, dated June 6 January 8, 2025</i>	<u>ATP_00080694</u>	<u>LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026</u>	<u>3/3 – Debtors propose stipulating into evidence</u>
JX-212	DX-107		<i>Expert Opinion of Michael Bloch KC on Cayman Islands Law</i>		The parties agree that pleadings from the Chancery case shall not be taken as truth of the matters asserted therein	
JX-213	DX-108		<i>Apertor Investment Memorandum</i>	Chancery JX95		
JX-214	DX-109		<i>Ascidian Capital Call</i>	Chancery JX824		
JX-215	DX-110		<i>Email from Anna Batarina to Anna Kolonehna Regarding Quarterly Report</i>	Chancery JX560		

JX-216	DX-111		<i>Deep Apple Series A Preferred Stock Purchase Agreement</i>	Chancery JX1329		
JX- 217-23 <u>8</u>	DX- 112-132	--	<i>Chancery Trial Transcript Emails Regarding Evercrisp Capital Call, dated October 16 January 23, 2025</i>	ATP_00080770	<u>LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026</u>	<u>3/3 – Debtors propose stipulating into evidence</u>
JX-218	DX-113		<i>Chancery Trial Transcript, dated October 17, 2025</i>			
JX-219	DX-114		<i>Stipulation and Order Governing Briefing on Plaintiff's Motion to Expedite</i>		The parties agree that pleadings from the Chancery case shall not be taken as truth of the matters asserted therein	
JX-220	DX-115		<i>Denied Order Granting Defendants' Motion to Stay Proceedings</i>		The parties agree that pleadings from the Chancery case shall not be taken as truth of the matters asserted therein	
JX- 221-23 <u>9</u>	DX- 116-133	--	<i>Alexian Post Trial Memorandum Opinion Emails Regarding Damages, C.A. No. 2020-1069-MTZ Evercrisp Capital Call, dated January 23, 2025</i>		<u>LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026</u>	<u>3/3 – Debtors propose stipulating into evidence</u>
JX-222	DX-117		<i>Alexian Post Trial Memorandum Opinion, C.A. No. 2020-1069-MTZ</i>		<u>LPs: Relevance</u>	
JX-223	DX-118		<i>Defendants' Motion to Continue Trial Dates</i>		The parties agree that pleadings from the Chancery case shall not be taken as truth of the matters asserted therein	
JX- 224-24 <u>0</u>	DX- 119-134	--	<i>Email from Michael Barlow to Blake Rohrbacher Regarding Chancery Litigation Scheduling, dated-</i>	ATP_00119671	<u>LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at</u>	<u>3/3 – Debtors propose stipulating into evidence</u>

February 25 ~~March 4~~, 2026

			<u>September 11, Portfolio Company Capital Calls, dated February 1, 2025</u>		<u>start of trial and first proposed to be added on 3/3/2026</u>	
<u>JX-225-24</u> <u>1</u>	<u>DX-120-135</u>	==	<u>Email from Melissa Thomas to Daniel Finkelman Emails Regarding Cayman Filings Portfolio Company Funding, dated June 2 April 24, 2025</u>	<u>ATP_00039403</u>	<u>LPs: Hearsay, Relevance; unduly prejudicial: not disclosed on JX list at start of trial and first proposed to be added on 3/3/2026</u>	<u>3/3 – Debtors propose stipulating into evidence</u>
<u>JX-226</u>	<u>DX-121</u>		<u>December 8, 2025 Email Regarding Chancery Order</u>			
<u>JX-227-24</u> <u>2</u>	<u>DX-122-136</u>	==	<u>Order Granting Defendants' Motion to Continue Trial Dates The Partnership's Skeleton Argument for the PTR Hearing on 17 December 2025</u>		The parties agree that pleadings from the <u>Chancery Cayman</u> case shall not be taken as truth of the matters asserted therein	<u>The Parties stipulate that this joint exhibit be admitted into evidence.</u>
<u>JX-228</u>	<u>DX-123</u>		<u>Q1 2025 ATP Fund Digest</u>			
			<u>Any other document or pleading filed in the above-captioned cases</u>		<u>Both parties reserve the right to object depending on document</u>	
			<u>Any exhibit necessary for impeachment or rebuttal purposes</u>		<u>Both parties reserve the right to object depending on document</u>	
			<u>Any exhibit identified or offered by any other party</u>		<u>Both parties reserve the right to object depending on document</u>	

AUTHORITIES

JOINT AUTHORITY	DEBTORS' AUTHORITY (DA)	RIGMORA AUTHORITY (RA)	DESCRIPTION	DOCKET/ BATES / OTHER IDENTIFIER	OBJECTIONS
JA-1	DA-1	==	<i>Voluntary Petition</i> , In re Sea Launch Company, LLC, No. 09-12153 (BLS) [Docket No. 1]	Docket No. 244-1	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-2	DA-2	==	<i>Declaration of Brett A. Carman in Support of Chapter 11 Petitions and First Day Motions</i> , In re Sea Launch Company, LLC, No. 09-12153 (BLS) [Docket No. 4]	Docket No. 244-2	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-3	DA-3	==	<i>Findings of Fact, Conclusions of Law, and Order Confirming the Debtors' Second Amended Plan of Reorganization</i> , In re Sea Launch Company, LLC, No. 09-12153 (BLS) [Docket No. 923]	Docket No. 244-3	
JA-4	DA-4	==	<i>Voluntary Petition</i> , In re MatlinPatterson Global Opportunities Partners II L.P., No. 21-11255 (DSJ) [Docket No. 1]	Docket No. 244-4	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-5	DA-5	==	<i>Declaration of Matthew Doheny, Chief Restructuring Officer of the Debtors, in Support of Chapter 11 Petitions and First Day Motions In Compliance with Local Rule 1007-2</i> , In re	Docket No. 244-5	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence

			MatlinPatterson Global Opportunities Partners II L.P., No. 21-11255 (DSJ) [Docket No. 2]		
JA-6	DA-6	==	<i>Findings of Fact, Conclusions of Law, and Order (I) Confirming the Debtors' Second Amended Joint Chapter 11 Plan of Liquidation and (II) Approving the Related Disclosure Statement on a Final Basis</i> , In re MatlinPatterson Global Opportunities Partners II L.P., No. 21-11255 (DSJ) [Docket No. 915]	Docket No. 244-6	
JA-7	DA-7	==	<i>Voluntary Petition</i> , In re Petra Offshore Fund LP, No. 10-15501 (SCC) [Docket No. 1]	Docket No. 244-7	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-8	DA-8	==	<i>Affidavit Pursuant to Local Rule 1007-2</i> , In re Petra Fund REIT Corp., No. 10-15500 (SCC) [Docket No. 2]	Docket No. 244-8	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-9	DA-9	==	<i>Order Confirming Second Amended Plan of Reorganization of Petra Fund REIT Corp. and Petra Offshore Fund, L.P., as Modified</i> , In re Petra Fund REIT Corp., No. 10-15500 (SCC) [Docket No. 259]	Docket No. 244-9	
JA-10	DA-10	==	<i>Chapter 15 Petition for Recognition of a Foreign Proceeding</i> , In re ECM Straits Fund I, LP (in Official	--	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence

			Liquidation), No. 23-12044 (MG) [Docket No. 1]	
JA-11	DA-11	=	<i>Order Granting Recognition and Relief in Aid of a Foreign Main Proceeding Pursuant to Sections 1504, 1509, 1515, 1517, 1520, and 1521 of the Bankruptcy Code</i> , In re ECM Straits Fund I, LP (in Official Liquidation), No. 23-12044 (MG) [Docket No. 15]	
JA-12	DA-12	=	<i>Declaration of Peter Sherwood in Support of Chapter 15 Petition for Recognition as Foreign Main Proceeding</i> , In re ECM Straits Fund I, LP (in Official Liquidation), No. 23-12044 (MG) [Docket No. 4]	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-13	DA-13	=	<i>Chapter 15 Petition for Recognition of a Foreign Proceeding</i> , In re Platinum Partners Value Arbitrage Fund L.P., No. 16-12925 (SCC) [Docket No. 1]	LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-14	DA-14	=	<i>Order Granting Recognition and Relief in Aid of a Foreign Bog Main Proceeding Pursuant to Sections 1504, 1509, 1515, 1517, 1520, and 1521 of the Bankruptcy Code</i> , In re Platinum Partners Value Arbitrage Fund L.P., No. 16-12925 (SCC) [Docket No. 27]	
JA-15	DA-15	=	<i>Declaration of Warren E.</i>	LPs: Object to inclusion

			<i>Gluck in Support of Recognition as Foreign Main Proceeding to Chapter 15 of the Bankruptcy Code, In re Platinum Partners Value Arbitrage Fund L.P., No. 16-12925 (SCC) [Docket No. 4]</i>		of declarations and pleadings from other cases as authorities or evidence
JA-16	DA-16	=	<i>In re Formation Group (Cayman) Fund I L.P (Cayman Grand Ct. Apr. 21, 2022)</i>	Docket No. 245-5	
JA-17	=	RX-66	Exempted Limited Partnership Law (2012 Revision)		
JA-18	DA-17	RX-67	Exempted Limited Partnership Act (2025 Revision)	Dkt. 125, Ex. M	
JA-19	DA-18	RX-68	Companies Act (2025 Revision)	Dkt. 125, Ex. CC	
JA-20	=	RX-69	<i>Re Aquapoint LP, CICA (Civil) Appeal No. 0014 of 2022, 04 October 2023</i>	Dkt. 126, Ex. B-34	
JA-21	DA-19	RX-70	<i>Kuwait Ports Authority v Port Link GP Limited [2023 (1) CILR 50]</i>	Dkt. 125, Ex. O	
JA-22	DA-20	=	<i>Re Aquapoint LP FSD 157 of 2021 (DDJ), KY 2022 GC 69</i>	Docket No. 126 Ex. B-32	
JA-23	DA-21	=	<i>Re Aquapoint LP, CICA (Civil) Appeal No. 0014 of 2022</i>	Docket No. 126 Ex. B-34	
JA-24	=	RX-71	<i>Re Belmont Asset Based Lending Ltd [2010] CIGC J0121-2</i>	Dkt. 125, Ex. C	
JA-25	=	RX-72	<i>Aquapoint LP (in Official Liquidation) v Xiaohu Fan, [2025] UKPC 56</i>	Dkt. 125, Ex. K	
JA-26	=	RX-73	<i>In Re One Thousand & One Voices Africa Fund I LP, KY</i>	Dkt. 125, Ex. D	

			2024 GC 62, 9 May 2024		
JA-27	<u>==</u>	RX-74	<i>Kuwait Ports Authority v Williams</i> [2024] UKPC 32	Dkt. 125, Ex. L	
JA-28	<u>==</u>	RX-75	<i>Gulf Investment Corp v The Port Fund LP</i> FSD 235 of 2019 and 13 of 2020, 19 June 2020	Dkt. 371, Ex. K	
JA-29	<u>==</u>	RX-169	McPherson & Keay's Law of Company Liquidation, 5th Ed. (excerpts)	Phillips Decl. B-50	
JA-30	<u>==</u>	RX-77	<i>FamilyMart China Holding Co Ltd (Respondent)</i> [2023] UKPC 33	Dkt. 125, Ex. EE	
JA-31	<u>==</u>	RX-78	<i>Re Free Rider Limited</i> [2010] 2 CILR 154	Dkt. 204, Ex. V	
JA-32	<u>==</u>	RX-133	Interpretation Act (1995 Revision)	Phillips Decl. Ex. B-01	
JA-33	<u>==</u>	RX-134	Companies Winding Up Rules (2023 Consolidation)	Phillips Decl. Ex. B-03	
JA-34	<u>==</u>	RX-135	Partnership Act (2025 Revision)		
JA-35	<u>==</u>	RX-136	Practice Direction No. 1 of 2018	Phillips Decl. Ex. B-07	
JA-36	<u>==</u>	RX-137	<i>Harrison v Tennant</i> (1856) 21 Beav 482	Phillips Decl. Ex. B-08	
JA-37	<u>==</u>	RX-138	<i>I.R.C. v Olive Mill Ltd</i> [1963] 1 WLR 712	Phillips Decl. Ex. B-09	
JA-38	<u>==</u>	RX-139	<i>Ebrahimi v Westbourne Galleries</i> [1973] A.C. 360, HL	Phillips Decl. Ex. B-10	
JA-39	<u>==</u>	RX-140	<i>Bristol and West Building Society v Mothew</i> [1998] Ch. 1	Phillips Decl. Ex. B-11	
JA-40	<u>==</u>	RX-141	<i>Hurst v Bryk</i> [2002] 1 A.C. 185 (HL)	Phillips Decl. B-12	

JA-41	<u>==</u>	RX-142	<i>In Re Lehman Brothers International (Europe) (in administration) (No 2)</i> [2009] EWCA Civ 1161; [2010] Bus. L.R. 489	Phillips Decl. B-13	
JA-42	<u>==</u>	RX-143	<i>Belmont Park Investments Pty Ltd v BNY Corporate Trustee Services Ltd</i> [2011] UKSC 38; [2012] 1 A.C. 383	Phillips Decl. B-14	
JA-43	<u>==</u>	RX-144	<i>Certain Ltd. Partners in Henderson PFI Secondary Fund II LP v Henderson PFI Secondary Fund II LP</i> [2012] EWHC 3259 (Comm); [2013] Q.B. 934	Phillips Decl. B-15	
JA-44	<u>==</u>	RX-145	<i>Revenue and Customs Commissioners v Anson</i> [2013] EWCA Civ 63; [2013] S.T.C. 55	Phillips Decl. B-16	
JA-45	<u>==</u>	RX-146	<i>Re Pan Ocean Co Ltd</i> [2014] EWHC 2124 (Ch); [2014] Bus. L.R. 1041	Phillips Decl. B-17	
JA-46	<u>==</u>	RX-147	<i>Singularis Holdings v. PricewaterhouseCoopers</i>	Phillips Decl. B-18	
JA-47	<u>==</u>	RX-148	<i>MacDonald v Carnbroe Estates Ltd</i> [2019] UKSC 57; [2020] S.C. (UKSC) 23	Phillips Decl. B-19	
JA-48	<u>==</u>	RX-149	<i>Lau v Chu</i> [2020] UKPC 24; [2020] 1 WLR 4656	Phillips Decl. B-20	
JA-49	<u>==</u>	RX-150	<i>Re Sova Capital Ltd</i> [2023] EWHC 452 (Ch); [2024] 1 All E.R. (Comm) 69	Phillips Decl. B-21	
JA-50	<u>==</u>	RX-151	<i>Mitchell v Al Jaber</i> [2025] UKSC 43; [2025] 3 W.L.R.	Phillips Decl. B-22	

			849		
JA-51	==	RX-152	Hopcraft v Close Brothers Ltd [2025] UKSC 33; [2025] 3 W.L.R. 423	Phillips Decl. B-23	
JA-52	==	RX-153	<i>Re Core VCT Plc</i> [2025] EWHC 2316 (Ch)	Phillips Decl. B-24	
JA-53	==	RX-154	<i>In Re ICP Strategic Credit Income Fund Limited</i> [2014] 1 CILR 314	Phillips Decl. B-26	
JA-54	==	RX-155	<i>Arnage Holdings Ltd v Walkers</i> [2019] 2 CILR 382	Phillips Decl. B-27	
JA-55	==	RX-156	<i>In Re LATAM Finance Limited</i> [2020] 2 CILR 787	Phillips Decl. B-28	
JA-56	==	RX-157	<i>In Re Duet Estate Partners LP</i> [2020] (2) CILR 390	Phillips Decl. B-29	
JA-57	==	RX-158	<i>Tianrui (International) Holding Company Ltd v China Shanshui Cement Group Ltd</i> [2020] 1 CILR 417	Phillips Decl. B-30	
JA-58	==	RX-159	<i>Re Padma Fund LP</i> [2021 (2) CILR 556]	Phillips Decl. B-31	
JA-59	==	RX-160	<i>Re ECM Straits Fund I LP</i> FSD 230 OF 2022 (RPJ), 20 December 2022	Phillips Decl. B-35	
JA-60	==	RX-161	<i>In Re Seahawk China Dynamic Fund</i> , KY 2022 GC 92, 9 August 2022	Phillips Decl. B-36	
JA-61	==	RX-162	<i>Re Rothenberg Ventures 2016 Feeder Fund LP</i> , KY 2024 GC 38, FSD 379 and 380 of 2023, 15 April 2024	Phillips Decl. B-38	
JA-62	==	RX-163	<i>Williams v Kuwait Ports Authority</i> , CICA (Civil) Appeal No 0011 of 2023, 15	Phillips Decl. B-40	

			August 2024		
JA-63	==	RX-164	<i>In Re ATP Life Science Ventures LP</i> [2025] CIGC (FSD) 106	Phillips Decl. B-43	
JA-64	==	RX-165	Goode on Principles of Corporate Insolvency Law, 5th Ed. (excerpts)	Phillips Decl. B-46	
JA-65	==	RX-166	Lewin on Trusts, 20th Ed. including First Supplement (excerpts)	Phillips Decl. B-47	
JA-66	==	RX-167	Lightman & Moss on The Law of Administrators and Receivers of Companies 6th. Ed. (excerpts)	Phillips Decl. B-48	
JA-67	==	RX-168	Lindley & Banks on Partnership, 21st Ed., incorporating First Supplement (excerpts)	Phillips Decl. B-49	
JA-68	DX-66	==	Disclosure Statement, <i>In re Sea Launch Company, LLC</i> , No. 09-12153 (BLS) [Docket No. 796]		LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-69	DX-67	==	Second Amended Plan, <i>In re Sea Launch Company, LLC</i> , No. 09-12153 (BLS) [Docket No. 795]		LPs: Object to inclusion of declarations and pleadings from other cases as authorities or evidence
JA-70	DA-22	==	<i>GPs Behaving Badly: Disputes Involving Cayman Exempted Limited Partnerships</i>		LPs: Object to the use of this client update to be treated as a legal authority.
JA-71	DA-23	==	<i>Schemes of Arrangement in the Cayman Islands</i>		LPs: Object to the use of this client update to be treated as a legal authority.
JA-72	DA-24	==	<i>Good News for Debtors Seeking Access to the Cayman Islands Restructuring Regime</i>		LPs: Object to the use of this client update to be treated as a legal authority.
JA-73	DA-25	==	<i>Cayman Islands Schemes of</i>		LPs: Object to the use of

			<i>Arrangement Now Available for Exempted Limited Partnerships Using the Restructuring Officer Regime</i>		this client update to be treated as a legal authority.
<u>JA-74</u>	<u>DX-2</u>	<u>RX-65</u>	<u>Judgment of Cayman Court, Dec. 22, 2025</u>	<u>Dkt. 117, Ex. F</u>	
<u>JA-75</u>	<u>=</u>	<u>RX-76</u>	<u>Re ATP Life Since Ventures LP [2025] CIGC (FSD) 106, Nov. 6, 2025 Judgment</u>	<u>Dkt. 125, Ex. E</u>	
<u>JA-76</u>	<u>=</u>	<u>RX-79</u>	<u>Unicorn Biotech Ventures One Ltd v ATP III GP Ltd (No. 4) [2025] CIGC (FSD) 124</u>	<u>Dkt. 125, Ex. F</u>	
<u>JA-77</u>	<u>=</u>	<u>RX-80</u>	<u>Unicorn Biotech Ventures One Ltd v ATP III GP Ltd (No.3) [2026] CIGC (FSD) 5 (Privilege Judgment)</u>	<u>Dkt. 371, Ex. A</u>	
<u>JA-78</u>	<u>DX-44</u>	<u>RX-88</u>	<u>Chancery Post-Trial Op., Dec. 5, 2025</u>	<u>Dkt. 125, Ex. H</u>	